Skyhawk Therapeutics CEO and leadership

Kathleen began her career by co-developing a treatment for Spinal Muscular Atrophy (SMA) as a pre-clinical scientist at the SMA Foundation. In this role she helped bring the first-ever small molecule therapeutic driving mRNA alternative splicing, to clinical trials in SMA. This drug candidate was bought by Roche in 2011 and Kathleen moved to Roche to work as a lead pre-clinical scientist. The SMA drug is now in pivotal clinical trials. Kathleen first-authored a Nature Communications paper describing the SMA compound mechanism (2017). Prior to her work in drug discovery and development, Kathleen completed a Fulbright Fellowship at the Swiss Federal Institute of Technology, ETH, and graduated with honors in Chemistry from Wellesley College.

Gary Martell is a Chief Financial Officer at Blu Homes, CFO at Dragonfly Therapeutics Inc, and Board Member at Blu Homes and is based in San Mateo, California. He has worked as CFO at UPEK, COO at Sun Microsystems, and CFO at Stion. Gary attended University of Massachusetts Amherst between 1980 and 1984.

Terry Connolly are a Chief Operating Officer at Skyhawk Therapeutics. They have worked as Executive Director:Business Development at CELGENE CORP DE. Terry studied at Ottawa and Mount Allison University.

Kathleen began her career by co-developing a treatment for Spinal Muscular Atrophy (SMA) as a pre-clinical scientist at the SMA Foundation. In this role she helped bring the first-ever small molecule therapeutic driving mRNA alternative splicing, to clinical trials in SMA. This drug candidate was bought by Roche in 2011 and Kathleen moved to Roche to work as a lead pre-clinical scientist. The SMA drug is now in pivotal clinical trials. Kathleen first-authored a Nature Communications paper describing the SMA compound mechanism (2017). Prior to her work in drug discovery and development, Kathleen completed a Fulbright Fellowship at the Swiss Federal Institute of Technology, ETH, and graduated with honors in Chemistry from Wellesley College.

Gary Martell is a Chief Financial Officer at Blu Homes, CFO at Dragonfly Therapeutics Inc, and Board Member at Blu Homes and is based in San Mateo, California. He has worked as CFO at UPEK, COO at Sun Microsystems, and CFO at Stion. Gary attended University of Massachusetts Amherst between 1980 and 1984.